Lamivudine Sandoz (Lamivudine)

Lamivudine is converted inside cells to its active triphosphate form, which mimics the natural nucleoside building blocks of viral DNA. When reverse transcriptase incorporates lamivudine into the growing viral chain, the missing 3′‑hydroxyl group stops further DNA elongation, thereby blocking replication of HIV and hepatitis B virus.

The appropriate dose of lamivudine is determined by the prescribing healthcare professional based on the specific indication, patient weight, renal function, and any concomitant medications. Patients should follow the exact dosing instructions provided by their prescriber and not adjust the dose on their own.

Data on lamivudine use during pregnancy and lactation are limited. Clinicians weigh the potential benefits for the mother against any possible risks to the fetus or infant. If treatment is deemed necessary, it is usually continued under close medical supervision, and breastfeeding decisions are made on a case‑by‑case basis.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor class and is often combined with other agents such as tenofovir or efavirenz. Compared with some alternatives, lamivudine has a favorable safety profile and a low pill burden, but resistance can develop if used without adequate combination therapy.

Lamivudine tablets should be stored at temperatures below 25 °C, protected from moisture and light. Keep the product in its original container until use, and avoid exposing it to excessive humidity or heat to maintain potency.

Lamivudine is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food, but patients should follow any specific instructions from their healthcare provider regarding timing and meal considerations.

Serious adverse events, although rare, include lactic acidosis, severe hepatomegaly with steatosis, pancreatitis, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid weight loss, severe fatigue, or skin blistering.

Lamivudine is contraindicated in individuals with known hypersensitivity to the drug or any of its components. Caution is also advised for patients with severe hepatic impairment, as the risk of liver‑related toxicity may be heightened.